1. Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001
- Author
-
Hammond TC, Lee RC, Oronsky B, Reid TR, Caroen S, Juarez TM, Gill J, Heng A, and Kesari S
- Subjects
covid-19 ,sars-cov-2 ,critical care ,ards ,rrx-001 ,nitric oxide ,viral diseases ,Medicine (General) ,R5-920 - Abstract
Terese Catherine Hammond,1,2 Raymond C Lee,1,3 Bryan Oronsky,4 Tony R Reid,4 Scott Caroen,4 Tiffany M Juarez,2 Jaya Gill,5 Annie Heng,2 Santosh Kesari1,2,5 1Providence St. Johns Health Center, Santa Monica, CA, USA; 2John Wayne Cancer Institute, Santa Monica, CA, USA; 3Cardiovascular Thoracic Institute, Keck School of Medicine of USC, Los Angeles, CA, USA; 4EpicentRx, Inc., La Jolla, CA, USA; 5Pacific Neuroscience Institute, Santa Monica, CA, USACorrespondence: Bryan Oronsky, EpicentRx, Inc, 11099 North Torrey Pines Road, La Jolla, CA, 92037, USA, Tel +1 858 947-6635, Fax +1 858 724-3080, Email boronsky@epicentrx.comAbstract: Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.Keywords: COVID-19, SARS-CoV-2, critical care, ARDS, RRx-001, nitric oxide, viral diseases
- Published
- 2022